



## Stockholders' Meeting June 3, 2010

**NASDAQ: ENMD**

**Presentation By  
Michael M. Tarnow, Executive Chairman**



# Forward-Looking Statements

---

I would like to remind everyone that statements in this presentation that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including risks relating to additional financing, early-stage product development, clinical trials, and those set forth in the Company's Securities and Exchange Commission filings.



## Financial Position: Year-End 2009

Twelve Months Ended December 31,

	2009	2008
Total revenues	\$ 5,284,058	\$ 7,477,219
Research & development	7,901,522	20,069,229
General & administrative	4,104,287	7,764,532
Acquired in-process R&D	-	2,000,000
Net Loss	(8,216,378)	(23,862,028)
Net loss per share attributable to common shareholders	\$ (0.11)	\$ (0.29)
Weighted avg. number of shares outstanding (basic)	87,757,765	86,479,768
Cash & short term investments	\$ 6,366,253	\$ 24,291,173

## Accomplishments at EntreMed: 2009 and Beyond

---

- Right-sized the company: 13 employees focused on ENMD-2076
- Carefully managing financial resources
- Patent issued for ENMD-2076 composition of matter
- Positive Phase 1 data for ENMD-2076 in solid tumors presented at ASCO-2009
- ENMD-2076 in multiple Phase I trials
- Multi-center Phase 2 trial initiated in ovarian cancer
- ENMD-2076 Orphan Drug Designations: ovarian cancer, multiple myeloma and acute myeloid leukemia (AML)
- Completed three registered financings to a single accredited investor for total gross proceeds of \$8.0 million


## 1Q10 vs. 1Q09: Carefully Managing Financial Resources

	Three Months Ended March 31,		
	2010	2009	Reduction
Research & development	\$ 843,953	\$1,953,460	57%
General & administrative	\$1,051,225	\$1,159,721	9%
Net Loss	(2,126,144)	(3,516,755)	40%
Net loss per share attributable to common shareholders	\$ (0.03)	(0.04)	

**Cash & short term investments** \$9,691,834 (excludes \$3 million financing in April 2010)

Successful completion of restructuring plan and improved operating results paved way for resources to accelerate and achieve milestones for ENMD-2076 in 2009 and 2010.


# ENMD-2076 – Potential for Meaningful Advance in Cancer Treatment



- First in class oral multi-kinase inhibitor
- Composition of matter patent, others pending
- Substantial activity in a variety of solid and hematological tumor types
- Acceptable safety profile
- Initiated Phase 2 in ovarian cancer

**Potential to achieve \$1B in sales across multiple indications**

# Substantial Commercial Potential: 2009 Sales of Marketed Small Molecule Kinase Inhibitors



Source: MedTrack, company sources

# ENMD-2076 Phase I Studies

## Solid Tumors

- Demonstrated clinical benefit in a variety of tumor types
  - Reductions in tumor volume
  - Reductions in tumor markers
  - Improvement in cancer related symptoms
- Oral, daily dosing
- Well-tolerated

## Acute Myeloid Leukemia (AML)

- Early data presented at AACR/EORTC/NCI meeting in 4Q09
  - ENMD-2076 associated with anti-leukemia activity
- Presentation of clinical data expected in late 2010

## Multiple Myeloma

- Currently enrolling
- Presentation of clinical data expected in late 2010

# ENMD-2076 Phase 2 Study in Ovarian Cancer

- Ovarian cancer selected as initial Phase 2 indication based on Phase 1 solid tumor study results
- Initiated multi-center Phase 2 study in April 2010
  - Six sites initiated and enrolling

Dana-Farber/Harvard Cancer Center	Memorial Sloan-Kettering Cancer Center	University of Chicago Medical Center
Indiana University Melvin and Bren Simon Cancer Center	Princess Margaret Hospital	University of Colorado

- Enrollment
  - Up to 60 patients
- Primary Endpoint
  - Progression-Free Survival (PFS) rate at 6 months

# ENMD-2076: Significant Clinical and Market Potential

- **Clinical development program into Phase 2**
  - Phase 1 study in solid tumors – complete
  - Phase 1 studies in multiple myeloma and leukemia – ongoing
  - Phase 2 multi-center study in ovarian cancer – ongoing
- **Significant therapeutic potential in a broad range of tumor types**
- **Strong intellectual property rights**
- **Orphan drug designation**
  - Ovarian Cancer
  - Multiple Myeloma
  - Acute Myeloid Leukemia (AML)

## ENMD-2076 in 2010

---

- **Peer-Reviewed Publications: Four anticipated by year end**
- **Presentations: Plans to submit abstracts for leukemia and multiple myeloma clinical studies for presentation at scientific meeting later this year**
- **Phase 2 ovarian cancer study**
  - Complete enrollment by year end
  - Present data in early 2011